Supply Chain

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on why she believes supply chain collaboration is becoming increasingly critical today.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, explains how he anticipates the evolving regulatory environment impacting the future of pharmaceutical development, especially in the context of emerging technologies like AI.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, describes why these pharma supply chain stakeholders are vital in understanding meaningful clinical outcomes.

These taxes on goods—with the potential to take effect in weeks or months—will vary by country, but rates could depend on regulations, industry subsidies, and other factors.

In the fourth part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the value of FDA guidance documents for manufacturers, along with the areas of CGT development that would benefit most from standardization.

The facilities are expected to offer pharma shipment support by addressing time and temperature-specific requirements.

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, dives into specific areas where FDA investment could have the greatest impact in accelerating approval timelines.

Trade & Channel Strategies conference explores the frontline issues related to strategy, distribution, and reimbursement—while digging into creative solutions to solve them.

Trump raises the import tax to 25% on the former—while restoring the latter to 25%—in a move that could potentially take effect on March 4.

Leaders with top third-party logistics providers discuss the evolving landscape for the sector in 2025—and the new strides made in their quest to help transform the pharma supply chain.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, discusses some of the other specific regulatory updates that drug developers be closely monitoring in the current landscape.

The agreement is centered around improving cell culture efficiency and CGT quality.

In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the challenges associated with meeting the FDA’s 2025 CGT forecasted approval goal.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, shares how the development of technology will help bolster the pharma logistics industry.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, describes what the approach of pharma companies should be amid the latest/pending tariffs imposed on Canada, Mexico, and China, along with their potential impact on the pharma supply chain.

The company cites a decline in sales and excess inventory as the main contributing factors.

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, shares how the imposed/pending trade tariffs impact pharma manufacturers.

However, the 10% tariff on imports from China went into effect this morning, with the nation imposing several of it own.

A report offers a comprehensive benchmarking and assessment of pharmaceutical manufacturer engagement with specialty pharmacies.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, explains what needs to be done in the United States in order to increase manufacturing output.

What implications will these have on the pharma supply chain?

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, describes the highlights of a recent pharma supply chain security and visibility report that his company released.

Can monitoring these dispensed Rxs via online search behavior help predict future GLP-1 use in the United States?

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, outlines the technological obstacles that lie ahead for the industry this year.

Donald Prentiss discusses the value of these pharmacies, especially during shortages.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Amanda Salindong, associate director of channel & distribution at Alnylam Pharmaceuticals, shares the elements that manufacturers should consider when selecting a 3PL.

The investment not only moves along the company’s efforts in advancing clinical studies, but also opens up 700 new jobs for the Greater Toronto area.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, describes the importance of the patient within the pharma supply chain.

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, discusses the origins of the compounding pharmacy, including what it seeks to accomplish.

Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.